

Attorney Docket No.: 10525.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK2004/000748		INTERNATIONAL FILING DATE 29 October 2004
APPLICANT(S)/INVENTOR(S)		
First Name	Middle Name	Family Name
1.Kim 2.Christel 3.	1. 2.Thea 3.	1.Borch 2.Jorgensen 3.
TITLE OF THE INVENTION		
Screening for Lipolytic Enzymes or Amidase Activity		

1. This is a first submission of items concerning a filing under 35 U.S.C. 371.
2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
3. The US has been elected.
4. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau. The application contains the following parts:

Specification	11 Pages
Abstract	1 Pages
Sequence Listing	0 Pages
Drawings	0 Pages
Total	12 Pages

5. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made; however, the time limit for making such amendments has NOT expired.
6. An application data sheet is enclosed.

10/576497
10/576497

7. Priority of Danish application no. PA 2003 01596 filed on October 29, 2003 is claimed under 35 U.S.C. 119(a)-(d).
8. The benefit of U.S. provisional application no. 60/516,619 filed on October 31, 2003 is claimed under 35 U.S.C. 119(e).
9. An oath or declaration of the inventors is submitted herewith.
10. An Information Disclosure Statement is submitted herewith.
11. An Assignment and Recordation Form Cover Sheet are submitted herewith.
12. A Preliminary Amendment is submitted herewith.
13. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
14. The assignee of the present application is:

Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark

Applicants request that the assignee information be included in the published patent application.

15. Direct all correspondence to Customer Number 25908.
16. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$0.00

CLAIMS FEE

Total Claims: 11 - 20 = 0 x 50 =	\$0.00
Independent Claims: 2 - 3 = 0 x 200 =	\$0.00
Total Claims Fee:	\$0.00

TOTAL NATIONAL FEE	\$1,000.00
--------------------	------------


10/576497

APR 15 Rec'd PCT/PTG 18 APR 2006

17. Please charge the required fee, estimated to be \$1,000, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 18, 2006



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

04-19-06



10/576497
IAP6 Rec'd PCT/PTO 18 APR 2006 T

Attorney Docket No. 10525.204-US

PATENT

IN THE UNITED STATES DESIGNATED ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK2004/000748

INTERNATIONAL FILING DATE: October 29, 2004

PRIORITY DATE: October 29, 2003

TITLE: Screening for Lipolytic Enzymes or Amidase Activity

APPLICANT(S) FOR RO/US: Borch et al.

EXPRESS MAIL CERTIFICATE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. EV 611574151 US

Date of Deposit: April 18, 2006

I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Executed Combined Declaration and Power of Attorney
3. Application Data Sheet
4. Preliminary Amendment
5. Information Disclosure Statement
6. Form PTO/SB/08A
7. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Julie Tabarovsky
(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097